{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T09:41:24Z","timestamp":1795081284696,"version":"4.10.2"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.eururo.2024.03.018","type":"journal-article","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T23:34:46Z","timestamp":1712187286000},"page":"10-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Prostate Radiotherapy in Low-volume Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis"],"prefix":"10.1016","volume":"86","author":[{"given":"Soumyajit","family":"Roy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gagan","family":"Fervaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Spratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar U.","family":"Kishan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Loblaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Malone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.D.","family":"Wallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6568-3346","authenticated-orcid":false,"given":"Scott C.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2024.03.018_b0005","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/ijc.34018","article-title":"Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476)","volume":"151","author":"James","year":"2022","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2024.03.018_b0010","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1200\/JCO.21.02517","article-title":"Orteronel for metastatic hormone-sensitive prostate cancer: a multicenter, randomized, open-label phase III trial (SWOG-1216)","volume":"40","author":"Agarwal","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.03.018_b0015","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2024.03.018_b0020","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.03.018_b0025","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","article-title":"Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: Long-term survival results from the STAMPEDE trial","volume":"30","author":"Clarke","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2024.03.018_b0030","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.03.018_b0035","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.03.018_b0040","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"Arches: A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.03.018_b0045","doi-asserted-by":"crossref","first-page":"e1003998","DOI":"10.1371\/journal.pmed.1003998","article-title":"Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: long-term results from the STAMPEDE randomised controlled trial","volume":"19","author":"Parker","year":"2022","journal-title":"PLoS Med"},{"key":"10.1016\/j.eururo.2024.03.018_b0050","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"Boev\u00e9","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.03.018_b0055","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eururo.2019.02.003","article-title":"Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis","volume":"76","author":"Burdett","year":"2019","journal-title":"Eur Urol"},{"issue":"17-suppl","key":"10.1016\/j.eururo.2024.03.018_b0060","doi-asserted-by":"crossref","first-page":"LBA5000","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA5000","article-title":"Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): results of PEACE-1, a phase 3 randomized trial with a 2x2 design","volume":"41","author":"Bossi","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.03.018_b0065","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1001\/jamaoncol.2022.7762","article-title":"First-line systemic treatment options for metastatic castration-sensitive prostate cancer: a living systematic review and network meta-analysis","volume":"9","author":"Bin","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2024.03.018_b0070","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.euo.2022.06.003","article-title":"Addition of docetaxel to androgen receptor axis\u2013targeted therapy and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: a network meta-analysis","volume":"5","author":"Roy","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2024.03.018_b0075","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1200\/JCO.22.00193","article-title":"Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer","volume":"40","author":"Armstrong","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.03.018_b0080","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","article-title":"Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Sweeney","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.03.018_b0085","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.03.018_b0090","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.03.018_b0095","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.eururo.2019.08.006","article-title":"Abiraterone in \u201chigh-\u201d and \u201clow-risk\u201d metastatic hormone-sensitive prostate cancer","volume":"76","author":"Hoyle","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.03.018_b0100","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.03.018_b0105","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.03.018_b0110","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.03.018_b0115","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.03.018_b0120","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.03.018_b0125","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2024.03.018_b0135","doi-asserted-by":"crossref","first-page":"pkab082","DOI":"10.1093\/jncics\/pkab082","article-title":"Real-world use of androgen-deprivation therapy: intensification among older Canadian men with de novo metastatic prostate cancer","volume":"5","author":"Wallis","year":"2021","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.eururo.2024.03.018_b0140","doi-asserted-by":"crossref","first-page":"8149","DOI":"10.3390\/curroncol30090591","article-title":"A real-world evidence study using Alberta-population-based data to describe treatment patterns for metastatic castration-sensitive prostate cancer patients (AWARENESS)","volume":"30","author":"Karim","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.eururo.2024.03.018_b0145","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3390\/biom11040492","article-title":"Current status and future perspectives of androgen receptor inhibition therapy for prostate cancer: a comprehensive review","volume":"11","author":"Kim","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.eururo.2024.03.018_b0150","doi-asserted-by":"crossref","first-page":"S963","DOI":"10.1016\/j.annonc.2023.09.2732","article-title":"1782P Prostate radiotherapy reduces long-term risk of obstructive uropathy in metastatic hormone sensitive prostate cancer (mHSPC): results from the STAMPEDE M1|RT comparison","volume":"34","author":"Jones","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2024.03.018_b0155","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijrobp.2017.02.004","article-title":"Duration of androgen deprivation in locally advanced prostate cancer: long-term update of NRG oncology RTOG 9202","volume":"98","author":"Lawton","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2024.03.018_b0160","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.eururo.2012.04.040","article-title":"The moving landscape of locally advanced prostate cancer: combination of external irradiation and endocrine treatment and\/or multimodal approach","volume":"62","author":"Bolla","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.03.018_b0165","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","article-title":"External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study","volume":"11","author":"Bolla","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.03.018_b0170","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","article-title":"Duration of androgen suppression in the treatment of prostate cancer","volume":"360","author":"Bolla","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.03.018_b0175","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1016\/S0140-6736(11)61095-7","article-title":"Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial","volume":"378","author":"Warde","year":"2011","journal-title":"Lancet"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283824022395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283824022395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T16:27:05Z","timestamp":1736872025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283824022395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0302283824022395"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2024.03.018","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prostate Radiotherapy in Low-volume Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2024.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}